+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Genetic Disorders Partnering 2014-2019: Deal trends, players and financials

  • ID: 2485356
  • Report
  • Region: Global
  • 300 Pages
  • CurrentPartnering
1 of 6
Global Genetic Disorders Partnering 2014-2019: Deal Trends, Players and Financials Report Provides Comprehensive Understanding and Unprecedented Access to the Genetic Disorders Partnering Deals and Agreements Entered Into by the World's Leading Healthcare

FEATURED COMPANIES

  • 4D Molecular Therapeutics
  • Bristol-Myers Squibb
  • Ferring Pharmaceuticals
  • Levo Therapeutics
  • PierianDx
  • Strongbridge Biopharma
  • MORE
Global Genetic Disorders Partnering 2014 to 2019 provides the full collection of Genetic Disorders disease deals signed between the world’s pharmaceutical and biotechnology companies since 2014.
  • Trends in Genetic Disorders partnering deals
  • Financial deal terms for headline, upfront and royalty by stage of development
  • Genetic Disorders partnering agreement structure
  • Genetic Disorders partnering contract documents
  • Top Genetic Disorders deals by value
  • Most active Genetic Disorders dealmakers
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Genetic Disorders disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Genetic Disorders deals.

The report presents financial deal terms values for Genetic Disorders deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Genetic Disorders deal making trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Genetic Disorders deal making since 2014 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Genetic Disorders deals since 2014. Deals are listed by headline value. The chapter includes the top 25 most active Genetic Disorders dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Genetic Disorders deals since 2014 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Genetic Disorders partnering deals by specific Genetic Disorders target announced since 2014. The chapter is organized by specific Genetic Disorders therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Genetic Disorders partnering deals signed and announced since 2014. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Genetic Disorders partnering and deal making since 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Genetic Disorders technologies and products.

Report scope

Global Genetic Disorders Partnering 2014 to 2019 is intended to provide the reader with an in-depth understanding and access to Genetic Disorders trends and structure of deals entered into by leading companies worldwide.

Global Genetic Disorders Partnering 2014 to 2019 includes:
  • Trends in Genetic Disorders deal making in the biopharma industry since 2014
  • Analysis of Genetic Disorders deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to hundreds of Genetic Disorders deal contract documents
  • Comprehensive access to over 350 Genetic Disorders deal records
  • The leading Genetic Disorders deals by value since 2014
  • Most active Genetic Disorders dealmakers since 2014
The report includes deals for the following indications: Cystic Fibrosis (CF), Down syndrome, Fragile X Syndrome, Hereditary angioedema, Huntington's disease, Rare genetic disorders, Neurofibromatosis, Sickle cell disease, plus other genetic indications.

In Global Genetic Disorders Partnering 2014 to 2019, available deals and contracts are listed by:
  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Stage of development at signing
  • Deal component type
  • Technology type
  • Specific therapy indication
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Genetic Disorders Partnering 2014-2019 report provides comprehensive access to available deals and contract documents for over 350 genetic disorders deals. Analyzing actual contract agreements allows assessment of the following:
  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are the sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • 4D Molecular Therapeutics
  • Bristol-Myers Squibb
  • Ferring Pharmaceuticals
  • Levo Therapeutics
  • PierianDx
  • Strongbridge Biopharma
  • MORE
Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Genetic Disorders deal making
2.1. Introduction
2.2. Genetic Disorders partnering over the years
2.3. Genetic Disorders partnering by deal type
2.4. Genetic Disorders partnering by industry sector
2.5. Genetic Disorders partnering by stage of development
2.6. Genetic Disorders partnering by technology type
2.7. Genetic Disorders partnering by therapeutic indication

Chapter 3 -Financial deal terms for Genetic Disorders partnering
3.1. Introduction
3.2. Disclosed financials terms for Genetic Disorders partnering
3.3. Genetic Disorders partnering headline values
3.4. Genetic Disorders deal upfront payments
3.5. Genetic Disorders deal milestone payments
3.6. Genetic Disorders royalty rates

Chapter 4 - Leading Genetic Disorders deals and dealmakers
4.1. Introduction
4.2. Most active in Genetic Disorders partnering
4.3. List of most active dealmakers in Genetic Disorders
4.4. Top Genetic Disorders deals by value

Chapter 5 - Genetic Disorders contract document directory
5.1. Introduction
5.2. Genetic Disorders partnering deals where contract document available

Chapter 6 - Genetic Disorders deal making by therapeutic target
6.1. Introduction
6.2. Deals by Genetic Disorders therapeutic target

Appendices
Appendix 1 - Directory of Genetic Disorders deals by company A-Z 2014 to 2019
Appendix 2 - Directory of Genetic Disorders deals by deal type 2014 to 2019
Appendix 3 - Directory of Genetic Disorders deals by stage of development 2014 to 2019
Appendix 4 - Directory of Genetic Disorders deals by technology type 2014 to 2019
Further reading on deal making
Deal type definitions

Table of figures
Figure 1: Genetic Disorders partnering since 2014
Figure 2: Genetic Disorders partnering by deal type since 2014
Figure 3: Genetic Disorders partnering by industry sector since 2014
Figure 4: Genetic Disorders partnering by stage of development since 2014
Figure 5: Genetic Disorders partnering by technology type since 2014
Figure 6: Genetic Disorders partnering by indication since 2014
Figure 7: Genetic Disorders deals with a headline value
Figure 8: Genetic Disorders deals with upfront payment values
Figure 9: Genetic Disorders deals with milestone payment
Figure 10: Genetic Disorders deals with royalty rates
Figure 11: Active Genetic Disorders deal making activity- 2014 to 2019
Figure 12: Top Genetic Disorders deals by value since 2014
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • 4D Molecular Therapeutics
  • Bristol-Myers Squibb
  • Ferring Pharmaceuticals
  • Levo Therapeutics
  • PierianDx
  • Strongbridge Biopharma
  • MORE
Global Genetic Disorders Partnering 2014 to 2019 provides the reader with the following key benefits:
  • In-depth understanding of Genetic Disorders deal trends since 2014
  • Access Genetic Disorders deal headline, upfront, milestone and royalty data
  • Research hundreds of actual contracts between Genetic Disorders partner companies
  • Comprehensive access to over 300 links to actual Genetic Disorders deals entered into by the world’s biopharma companies
  • In-depth review of Genetic Disorders deals entered into by the top 25 most active dealmakers
  • Benchmark the key deal terms companies have agreed in previous deals
  • Identify key terms under which companies partner Genetic Disorders opportunities
  • Uncover companies actively partnering Genetic Disorders opportunities
Note: Product cover images may vary from those shown
5 of 6
  • 4D Molecular Therapeutics
  • AAVLife
  • Abbvie
  • Abby Grace Foundation
  • Abeona Therapeutics
  • AdAlta
  • Addex Therapeutics
  • ADMA Biologics
  • Aequus Pharmaceuticals
  • Affectis Pharmaceuticals
  • Affymetrix
  • Agena Bioscience
  • Agilis Biotherapeutics
  • AGTC
  • AiLife Diagnostics
  • Akcea Therapeutics
  • Alana Healthcare
  • Alcyone Lifesciences
  • Aldeyra Therapeutics
  • Alexion Pharmaceuticals
  • AllCells
  • Allergan
  • Alnylam Pharmaceuticals
  • Altamira Pharma
  • Altius Institute for Biomedical Sciences
  • Ambry Genetics
  • American Heart/Stroke Association
  • American Society of Human Genetics
  • AmerisourceBergen
  • Amgros
  • Amicus Therapeutics
  • AMO Pharma
  • AmorChem
  • Angion Biomedica
  • Annapurna Therapeutics
  • Antabio
  • Anthera Pharmaceuticals
  • ANZAC Reserach Institute
  • AOP Orphan Pharmaceuticals
  • APG Bio
  • Arbor Biotechnologies
  • Arch Biopartners
  • Arcturus Therapeutics
  • Aridis Pharmaceuticals
  • Ariosa Diagnostics
  • ArmaGen
  • ArQule
  • Aruvant Sciences
  • Asklepion Pharmaceuticals
  • Astellas Pharma
  • AstraZeneca
  • Attain Health
  • Auburn University
  • Audentes Therapeutics
  • Bambino Gesu Children’s Hospital
  • Bayer
  • Baylor College of Medicine
  • Baylor Genetics
  • Berg
  • Beyond Batten Disease Foundation
  • BGI Americas
  • Bicycle Therapeutics
  • biOasis Technologies
  • BioAxone Therapeutic
  • BioBlast Pharma
  • Biogen
  • Biohealth Innovation
  • Bioiatriki
  • BioMarin Pharmaceutical
  • Biomedical Catalyst Fund (UK)
  • Biomnis
  • BioPontis Alliance
  • BioRealm
  • BioSensics
  • Bioverativ
  • BioXcel
  • Bloom Burton
  • Bluebird Bio
  • Blueprint Medicines
  • Boehringer Ingelheim
  • Brammer Bio
  • BridgeBio Pharma
  • Brigham and Women's Hospital
  • Bristol-Myers Squibb
  • Buck Institute for Age Research
  • California Institute for Biomedical Research
  • California Institute for Regenerative Medicine
  • Calimmune
  • Camurus
  • CANbridge Life Sciences
  • Cancer Prevention Pharmaceuticals
  • Capnia
  • CARB-X
  • Cardinal Health
  • Case Western Reserve University
  • Casma Therapeutics
  • Castle Creek Pharmaceuticals
  • Celgene
  • Center for Human Genetics and Laboratory Medicine
  • Centers for Disease Control and Prevention
  • Centogene
  • Centre for Drug Research and Development (CDRD)
  • CFTechnology.org
  • Charcot-Marie-Tooth Association
  • CHDI Foundation
  • ChemDiv
  • Children's Hospital Los Angeles
  • Children's Hospital of Philadelphia
  • Children's National Health System
  • Children’s Hospital Oakland Research Institute (CHORI)
  • Chondrial Therapeutics
  • Cincinnati Children’s Hospital Medical Center
  • Claire's Place Foundation
  • Claritas Genomics
  • Clementia Pharmaceuticals
  • Clinic for Special Children
  • Clinigen
  • Columbia University Medical Center
  • Concert Pharmaceuticals
  • Confluence Pharmaceuticals
  • Congenica
  • Corbus Pharmaceuticals
  • Courtagen Life Sciences
  • CRISPR Therapeutics
  • CTD Holdings
  • Cure Duchenne
  • Cure Sanfilippo Foundation
  • CURx Pharmaceuticals
  • Cyclacel Pharmaceuticals
  • Cypher Genomics
  • Cystic Fibrosis Foundation
  • Cystic Fibrosis Foundation Therapeutics
  • Cystic Fibrosis Trust
  • Cystinosis Research Foundation
  • Dainippon Sumitomo Pharma
  • Daktari Diagnostics
  • Dalton Pharma Services
  • DarioHealth
  • DaRui Biotech
  • David and Barbara Roux
  • DBV Technologies
  • de Duve Institute
  • DefiniGEN
  • Department of Health and Human Services
  • Department of Veterans Affairs
  • Dermelix Biotherapeutics
  • Dicerna Pharmaceuticals
  • Dilaforette
  • Dimension Therapeutics
  • DMS Health Technologies
  • Duchenne Therapy Network
  • Duke University
  • Dynacure
  • Dystrophic Epidermolysis Bullosa Research Association of America
  • Edico Genome
  • Edimer Pharmaceuticals
  • Eiger BioPharmaceuticals
  • Elevian
  • Elexopharm
  • Eli Lilly
  • Elixirgen
  • Elucigene
  • Emergent BioSolutions
  • Emmaus Life Sciences
  • Emmaus Medical
  • Emory University
  • EnBiotix
  • Enterprise Therapeutics
  • Enzyvant Science
  • EpiDestiny
  • Ergomed
  • Erytech
  • EspeRare Foundation
  • Essentialis
  • Esteve
  • Eureka Genomics
  • EUSA Pharma
  • Evotec
  • Ewopharma
  • Exemplar Genetics
  • Fabric Genomics
  • Facio Therapies
  • Ferring Pharmaceuticals
  • Fertility SOURCE Companies
  • Fibrocell Science
  • Flemish agency for Innovation by Science and Technology
  • Fluidigm
  • Fondazione Telethon
  • Food and Drug Administration (FDA)
  • Fortress Biotech
  • Foundation For Angelman Syndrome Therapeutics
  • Foundation for the Children of the Californias
  • Fox Chase Cancer Center
  • FRAXA Research Foundation
  • Friedreichs Ataxia Research Alliance
  • FSHD Global Research Foundation
  • Fudan University
  • Fujitsu Laboratories
  • Fulcrum Therapeutics
  • Fulgent Genetics
  • Galapagos
  • Gamida Cell
  • Geisinger Health System
  • Genable Technologies
  • Genea Biocells
  • GeneDX
  • GenePeeks
  • Genethon
  • Genetic Alliance
  • Geneva University Hospitals
  • Genoma
  • Genome Institute of Singapore
  • Genomic Vision
  • Genzyme
  • George Washington University
  • Gilead Sciences
  • GlaxoSmithKline
  • Global Blood Therapeutics
  • GNS Healthcare
  • Good Start Genetics
  • Grace Wilsey Foundation
  • Great Ormond Street Hospital (GOSH)
  • GtreeBNT
  • Harvard University
  • Helix
  • Heptares Therapeutics
  • Hereditary Neuropathy Foundation
  • Hillhurst Biopharmaceuticals
  • Horizon Discovery
  • Icagen
  • Icahn School of Medicine at Mount Sinai
  • Illumina
  • Immuneering
  • ImmunoQure
  • Imperial College London
  • Imperial Innovations
  • In-Depth Genomics
  • Indiana University
  • Indiana University-Purdue University Indianapolis
  • Indian Institute of Science Education and Research
  • InformedDNA
  • Innovate UK
  • Inova Translational Medicine Institute
  • Inserm
  • Inserm Transfert
  • Insight Centre for Data Analytics
  • Insilico
  • Insmed Inc
  • Institute for Genome Statistics and Bioinformatics
  • Institute of Child Health
  • Institute of Human Genetics
  • Intel
  • Intrexon
  • Intrinsic LifeSciences
  • Invitae
  • Ionis Pharmaceuticals
  • ISIS Innovation
  • Israeli Ministry of Industry and Commerce
  • IXICO
  • Jackson Laboratory
  • Janssen Pharmaceuticals
  • Jazz Pharmaceuticals
  • Jeffrey Modell Foundation
  • Juvenescence
  • K-PAX Pharmaceuticals
  • Kadmon Pharmaceuticals
  • Kamada
  • Kings College London
  • Komodo Health
  • La Jolla Pharmaceutical
  • Lannett
  • Laurent Pharmaceuticals
  • Lead Discovery Center
  • Leadiant Biosciences
  • Leidos
  • Lenus Therapeutics
  • Les Laboratoires Servier
  • Levo Therapeutics
  • LFB Biotechnologies
  • Ligand Pharmaceuticals
  • Linda Crnic Institute for Down Syndrome
  • Louisiana State University
  • Lumicera Health Services
  • Luminex
  • Lundbeck
  • Lysogene
  • Mallinckrodt Pharmaceuticals
  • ManRos Therapeutics
  • Marnier-Lapostolle Foundation
  • Massachusetts Eye and Ear Infirmary
  • Massachusetts General Hospital
  • Massachusetts Institute of Technology
  • Matinas Biopharma
  • Mauli Ola Foundation
  • Maxcyte
  • Maxor National Pharmacy
  • McGill University
  • McKesson
  • Medgenics
  • Medical College of Wisconsin
  • Medical University of South Carolina
  • Medison Pharma
  • MedPharm
  • MeiraGTx
  • Merck and Co
  • Merck KGaA
  • Mitsubishi Tanabe Pharma
  • Moderna Therapeutics
  • Molecular Stethoscope
  • Morphic Therapeutic
  • Mount Sinai Medical Center
  • Murdoch Childrens Research Institute
  • Mustang Bio
  • Mylan Laboratories
  • Nanopharmacia
  • NantHealth
  • Napa Therapeutics
  • Natera
  • National Center for Advancing Translational Sciences (NCATS)
  • National Heart
  • Lung and Blood Institute
  • National Human Genome Research Institute
  • National Institute of Allergy and Infectious Diseases
  • National Institute of Child Health and Human Development
  • National Institute of Mental Health
  • National Institute of Neurological Disorders and Stroke
  • National Institute on Aging
  • National Institutes of Health
  • National Newspaper Publishers Association
  • National Organization for Rare Disorders
  • National Psoriasis Foundation
  • National Science Foundation
  • National Taiwan University Hospital
  • Nationwide Children’s Hospital
  • Navitas
  • Necker Hospital
  • Neurocrine Biosciences
  • NeuroCycle Therapeutics
  • NeuroPointDX
  • Neurotrope BioScience
  • NeuroVive Pharmaceutical
  • New York Blood Center
  • New Zealand Pharmaceuticals
  • NextCODE Health
  • NextGxDx
  • NightstaRx
  • Nippon Chemiphar
  • Nippon Shinyaku
  • Novartis
  • Novation
  • Novogen
  • Novo Nordisk
  • Novoteris
  • Numedicus
  • Onconova Therapeutics
  • Oraxion Therapeutics
  • Orchard Therapeutics
  • ORIG3N
  • Origin Biosciences
  • Orsini Healthcare Specialty Pharmacy
  • Ovid Therapeutics
  • Oxford BioMedica
  • Pacific Biosciences
  • Palvella Therapeutics
  • ParcelShield
  • Parion Sciences
  • PARI Pharma
  • Paris Descartes University
  • Patheon
  • Pathway Genomics
  • PatientsLikeMe
  • PCT
  • PerkinElmer
  • Perlara
  • Perrigo
  • Personalis
  • Pfizer
  • PharmaCell
  • Pharnext
  • PierianDx
  • PlasmaTech Biopharmaceuticals
  • Plasticell
  • PoC Capital
  • Polyphor
  • Portable Genomics
  • Prader-Willi Research
  • PreventionGenetics
  • Progenitor Cell Therapy
  • Progeria Research Foundation
  • ProPath
  • Prophylix Pharma
  • ProQR Therapeutics
  • Proteostasis Therapeutics
  • Prothelia
  • PSC Biotech
  • PTC Therapeutics
  • PWNHealth
  • Q-State Biosciences
  • Qiagen
  • QoL Medical
  • QR Pharma
  • Queen Mary University of London
  • Questcor Pharmaceuticals
  • Radboud University Nijmegen Medical Centre
  • Rady Children's Institute for Genomic Medicine
  • RaNA Therapeutics
  • Raptor Pharmaceutical
  • Rare Diseases Clinical Research Network
  • Rare Genomics Institute
  • Recombinetics
  • Recordati
  • Recursion Pharmaceuticals
  • Regenacy Pharmaceuticals
  • Regeneron Genetics Center
  • Regeneron Pharmaceuticals
  • Regenxbio
  • ReGenX Biosciences
  • Repligen
  • Reproductive Medicine Associates of New York
  • RespirTech
  • Retrophin
  • RetroSense Therapeutics
  • Rett Syndrome Research Trust
  • rEVO Biologics
  • Rhythm Pharmaceuticals
  • Roche
  • Roche Diagnostics
  • Rockefeller University
  • Rocket Pharmaceuticals
  • Rockland Immunochemicals
  • Roivant Sciences
  • RUCDR Infinite Biologics
  • Salud Interactiva
  • Sangamo BioSciences
  • Sanofi
  • Sanofi-Genzyme BioVentures
  • Santhera Pharmaceuticals
  • Saphetor
  • Sarepta Therapeutics
  • Scarab Genomics
  • Scholar Rock
  • Scripps Research Institute
  • Selecta Biosciences
  • Sema4
  • Semmelweis University
  • Sentieon
  • Sequenom
  • Seres Therapeutics
  • Sharp Edge Labs
  • Shionogi Pharma
  • Shire Laboratories
  • Shire Pharmaceuticals
  • Singulex
  • Sirona Biochem
  • Skyhawk Therapeutics
  • SOM Biotech
  • Sound Pharmaceuticals
  • Spark Therapeutics
  • SpringWorks Therapeutics
  • St. Jude Children's Research Hospital
  • Stanford University
  • Stanford University School of Medicine
  • Stealth Therapeutics
  • StemCyte
  • StrideBio
  • Strongbridge Biopharma
  • Sturge-Weber Foundation
  • Sucampo AG
  • Sucampo Pharmaceuticals
  • Sutter Health
  • Swedish Orphan Biovitrum
  • Synteract
  • T-TOP Clinical Research
  • Taiba
  • Takeda America Holdings
  • Takeda Pharmaceutical
  • Talee Bio
  • TARGET PharmaSolutions
  • Taro Pharmaceuticals
  • Tasly Pharmaceuticals
  • Team Sanfilippo
  • Tekmira Pharmaceuticals
  • Tel Aviv University
  • Tetra Discovery Partners
  • Teva Pharmaceutical Industries
  • Texas Children’s Hospital
  • The BioCollective
  • The HUB Foundation
  • The Nemours/Alfred I duPont Hospital for Children
  • Theraly Fibrosis
  • Tillotts Pharma
  • Traffick Therapeutics
  • Transgenomic
  • Transition Therapeutics
  • Tripex Pharmaceuticals
  • Tuberous Sclerosis Alliance (TS Alliance)
  • Turing Pharmaceuticals
  • UK Cystic Fibrosis Gene Therapy Consortium
  • Ultragenyx Pharmaceuticals
  • UNeMed
  • UniQure
  • UnitedHealthcare
  • Universite catholique de Louvain
  • Universite Laval
  • University College Dublin
  • University College London
  • University of Alabama
  • University of Auckland
  • University of Bonn
  • University of California Irvine
  • University of California Los Angeles
  • University of California San Francisco
  • University of Cambridge
  • University of Cincinnati
  • University of Colorado
  • University of Colorado Denver
  • University of Edinburgh
  • University of Florida
  • University of Massachusetts
  • University of Massachusetts Medical School
  • University of Nebraska
  • University of Nevada
  • University of North Carolina
  • University of Notre of Dame
  • University of Oxford
  • University of Pennsylvania
  • University of Pittsburgh
  • University of Quebec
  • University of South Florida
  • University of Texas Southwestern Medical Center
  • University of Toledo
  • University of Utah
  • University of Washington
  • University of Zambia
  • University of Zurich
  • US Bioservices
  • Vaccinex
  • Valeant Pharmaceuticals
  • Valeo Pharma
  • Vanda Pharmaceuticals
  • Vanderbilt University
  • Vertex Pharmaceuticals
  • Victorian Clinical Genetics Services
  • Viking Therapeutics
  • Vinnova
  • Visikol
  • Voyager Therapeutics
  • Wake Forest University
  • Warren Family Research Center for Drug Discovery and Development
  • Washington University in St Louis
  • WAVE Life Sciences
  • Weill Cornell Medical College
  • Wellcome Trust
  • Wired Holdings
  • WuXi Biologics
  • WuXi NextCODE Genomics
  • X4 Pharmaceuticals
  • XL-Protein
  • Yale University
  • Yungjin Pharmaceutical
  • YuYang DNU
  • Zoetis
  • Zogenix
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/2485356
Adroll
adroll